cd 38

CD38 inhibitor 1 is a potent CD38 inhibitor that is effective against human CD38 (IC50 value is 7.3 nM) and mouse CD38 (IC50 value is 1.9 nM).

CD38 inhibitor 2 is an effective CD38 inhibitor (IC50 = 10–100 nM) suitable for cancer and immunology research.

CD38 Inhibitor 3 (compound 1), with an IC50 of 11 nM, is a potent agent that enhances mitochondrial biogenesis, diminishes lactate levels, and augments both NAD+ content and Nrf2 expression. In a Pus1 -/- mouse model of mitochondrial myopathy, it also elevates muscle function and bolstering exercise capacity [1].

6-Alkyne-F-araNAD is an irreversible CD38 inhibitor that aids in better visualization of intracellular CD38 localization when used alongside other fluorescent probes (such as SR101−F-araNMN).

Kuromanin chloride (Chrysontemin chloride) is potent antioxidants and free radical scavengers, may act as modulators of gene regulation and signal transduction pathways.

Ara-F-NAD+, an arabino analogue of NAD + , is a potent, slow-binding CD38 NADase inhibitor, with a K i of 169 nM.

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system, a highly expressed protein in multiple myeloma. It exhibits antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, directly inducing apoptosis without crosslinking. Isatuximab inhibits CD38 extracellular enzyme activity, affecting various cellular functions.

RBN013209 is a potent CD38 inhibitor. RBN013209 is useful in the treatment of cancer.

MK-0159 is an orally available, highly potent CD38 inhibitor with myocardial injury protection for the study of cardiac ischemia and reperfusion injury.

Ara-F-NAD+ sodium, an arabino analogue of NAD+, serves as a potent, reversible, and slow-binding inhibitor of the CD38 NADase [1] [2].

Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.

Modakafusp alfa (TAK-573) is a humanized anti-CD38 IgG4 monoclonal antibody fused with 2 attenuated IFNα2b molecules, being researched for potential use in treating multiple myeloma [1].

Lumrotatug is a human-derived IgG1κ monoclonal antibody designed to target CD38. The isotype control for Lumrotatug is HumanIgG1kappa, Isotype Control.

SAR442257 is a humanized IgG4-S228P (κ type) monoclonal antibody designed to target CD38 on the surface of multiple myeloma cells, while also co-stimulating CD3 and CD28 molecules on T cells.

Luteolinidin chloride is a natural product. It is a potent CD38 inhibitor which can protect the heart against I/R injury with preservation of eNOS function and prevention of endothelial dysfunction in vivo.

Noraramtide (BHV-1100) is an antibody recruiting molecule that specifically binds to the CD38 molecule to recruit natural killer (NK) cells. This interaction enhances the NK cells' ability to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while preventing mutual NK cell destruction. Noraramtide is utilized in research on autologous cancer immunotherapy.

Anti-RatCD4Antibody (OX-38) is an IgG2a, κ antibody inhibitor derived from mice, specifically targeting rat CD4.

Anti-CDCP1/CD318 Antibody (38 E11) is a human-derived antibody expressed in CHO cells, targeting CDCP1/CD318. It features a huIgG1 heavy chain and a huκ light chain with an estimated molecular weight (MW) of 150 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

NCD38 is a selective LSD1 (lysine-specific demethylase 1) inhibitor that activates super-enhancers and myeloid cell development programmes, exhibiting anti-leukaemia activity.

UCD38B HCl is a cell-permeable intracellular uPA inhibitor that acts by killing proliferative and non-proliferative high-grade glioma cells by programmed necrosis.

Hexamethonium tartrate is a nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.

NCD38 TFA serves as a selective inhibitor of LSD1 [1] [2].